Lattice Biologics Launches AmnioVisc Amniotic Fluid Viscosupplement

By Julie A. Vetalice

Lattice Biologics launched AmnioVisc™, a minimally-processed amniotic fluid supplement for the treatment of osteoarthritis pain in all joints.

Results from a 275-patient study demonstrated lasting pain relief and fewer adverse events than hyaluronic acid viscosupplements, the current standard of care, including single-injection MONOVISC™, 3-injection ORTHOVISC® and Synvisc-One®.

Study highlights indicate:

  • At 30 days, 75% of AmnioVisc recipients reported pain relief that was >40%
  • At 90 days, the number of AmnioVisc patients reporting >40% relief increased to nearly 80%
  • At 180 days, 67% of AmnioVisc patients maintained >40% pain relief

 

AmnioVisc™ is administered in a single injection regimen and is available for distribution throughout the U.S., Canada and internationally.

Sources: Lattice Biologics, Inc.; ORTHOWORLD Inc.

Product Labels: Viscosupplement

Tags: Product Launch